Skip to content
OpenCapital
Get started

Arcus Biosciences RCUS Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

SPS Commerce logo
SPS CommerceSPSC
$4.87M+54.2%
AvePoint, Inc. logo
AvePoint, Inc.AVPT
$4.39M+4.3%
Q2 Holdings logo
Q2 HoldingsQTWO
$45.49M+26.0%
AMN Healthcare logo
AMN HealthcareAMN
-$4.41M-312%
Calix logo
CalixCALX
$675K-80.6%
Rackspace Technology, Inc. logo
Rackspace Technology, Inc.RXT
$35.6M+483%

Other financials

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation

See full
Market cap$3.62B+226%
Enterprise value$3.53B+275%
P/S15.4×+7.5×

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%—

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcus Biosciences's increase (decrease) in contract liabilities and current deferred income?
Arcus Biosciences (RCUS) reported increase (decrease) in contract liabilities and current deferred income of -$17M in Q1 2026.
How has Arcus Biosciences's increase (decrease) in contract liabilities and current deferred income changed year-over-year?
Arcus Biosciences's increase (decrease) in contract liabilities and current deferred income increased by 39.3% year-over-year, from -$28M to -$17M.
What is the long-term trend for Arcus Biosciences's increase (decrease) in contract liabilities and current deferred income?
Over 3 years (2021 to 2025), Arcus Biosciences's increase (decrease) in contract liabilities and current deferred income has grown at a -13.3% compound annual growth rate (CAGR), from -$368M to -$240M.